Atazanavir atazanavir is a structural analog of the transition state during which the bond between a phenylalanine and proline is broken. Humans do not have any enzymes that break bonds between phenylalanine and proline, so this drug will not target human enzymes. Atazanavir is available as a 150 mg capsule, 200 mg capsule, 300 mg capsule, and 50 mg oral powder packet. The 300 mg capsule should reduce pill burden, as one 300 mg capsule may replace two 150 mg capsules. Atazanavir Atazanavir, sold under the trade name Reyataz among others, is an antiretroviral medication used to treat and prevent HIV/AIDS.
Nitroglycerin (drug) with the use of nitroglycerin to alleviate angina pectoris and reduce blood pressure, and showed that the accompanying headaches occurred as a result of overdose. Murrell began treating patients with small doses of GTN in 1878, and the substance was widely adopted after he published his results in "The Lancet" in 1879. The medical establishment used the name "glyceryl trinitrate" or "trinitrin" to avoid alarming patients, because of a general awareness that nitroglycerin was explosive. Overdoses may generate methemoglobinemia. Nitroglycerin (drug) Nitroglycerin, also known as glyceryl trinitrate (GTN), is a medication used for heart failure, high blood pressure, and to